Future considerations in HTS: The acute effect of chronic dilemmas

Drug Discovery Today

Volumn 3, Issue 7, 1998, Pages 304-312

  Sills, Matthew A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LEAD;

COST BENEFIT ANALYSIS; DRUG MANUFACTURE; DRUG SCREENING; ENZYME ACTIVITY; INSTRUMENTATION; REVIEW;

EID: 0031851132     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(98)01202-1     Document Type: Review

References (4)

1. Oldenburg K.R.et al. J. Biomol. Screening. 3:1998;55-62.
2. Cook N.D. Drug Discovery Today. 1:1996;287-294.
3. Hemmila I., Webb S. Drug Discovery Today. 2:1997;373-381.
4. Kolb J.M., Yamanaka G., Manly S.P. J. Biomol. Screening. 1:1996;203-210.